Chondroitin sulfate, Glucosamine hydrochloride, and the two in combination for Kashin-Beck Disease: a cluster-randomised, placebo-controlled study

The comprehensive control of Kashin-Beck disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001480

Enrollment

Unknown

Registered

2011-08-22

Start date

2009-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kashin-Beck disease

Interventions

1:chondroitin sulfate

2:glucosamine hydrochloride

3:glucosamine plus chondroitin sulfate

4:placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: We recruited patients with KBD who were capable of giving informed consent and who planned to live in the trial area for at least 6 months.

Exclusion criteria

Exclusion criteria: Patients were excluded if they had taken any medicine for KBD during 3 months before enrollment, predominant patellofemoral disease, a history of clinically significant trauma or surgery to the index joint, coexisting disease that could preclude successful completion of the trial, or pregnant.

Design outcomes

Primary

Measure	Time frame
20% and 50% decrease in the summed score for the Western Ontario and McMaster Universities Osteoarth;	—

Secondary

Measure	Time frame
scores for the pain, stiffness and function subscales of WOMAC, 12-item Short-Form General Health Su;	—

Countries

China

Contacts

Public ContactBirong Dong

birongdong@163.com+86 18980601332

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 26, 2026